SOCIAL MEDIA IMPACT of ASCO 2024

The 2024 ASCO annual meeting took place from May 31st  to June 4th, 2024, in Chicago, Il, USA. This year’s event was primarily an in-person event with virtual broadcasts available. The program at a glance is available here. As has been the case since 2019 we will be assessing the impact of the conference online: 

From the view of HCPs:

• Conditions and drugs most discussed during the listening period
• HCPs' posts that generated the most engagement
• Most mentioned clinical trials by HCPs
• Focus on multiple myeloma and molecular testing

From the view of pharma companies:

• Top pharma companies (in terms of mentions)

Scope

The scope of the analysis is focused on mentions coming worldwide.*

A total of 107K mentions were recorded during the listening period from May 24th, 2024, to June 11th, 2024 (one week before and after the conference).

All mentions came from X (formally known as Twitter).

A total of 12K unique authors were identified.

*#asco24 OR #asco2024 OR (asco NEAR/2 (2024 OR 24))

 Methodology

**#asco24 OR #asco2024 OR (asco NEAR/2 (2024 OR 24))

Volume of conversations

There was a strong decrease 31,32% increase in overall mentions when compared to ASCO 2023. Amongst the user types classified in this congress tracking, HCPs represent the bulk of the conversations at 74%.

Top posts (from HCPs)

Most liked: This post, published before the conference, is anticipating study results in thoracic cancer with a special mention towards the LAURA trial as well as a detailed algorithm of the current state of treatment in lung cancer.

Most reposts: This post highlighted the ESOPEC clinical trial which showed extended overall survival with the FLOT perioperative chemotherapy regimen in adenocarcinoma of the oesophagus.

Most replied to: The post receiving the most comments were congratulatory messages towards Dr. Manochakian receiving the FASCO designation

Top mentioned cancers and molecules (from HCPS)

SOV of clinical trials most discussed (# of mentions) : lung cancer dominates

Focus on multiple myeloma

This year’s ASCO conference was heavily focused on monoclonal antibody and more particularly daratumumab and antibody drug conjugate studied in the DREAMM-7 and 8 trials.

The IMROZ clinical trial, the most mentioned  showing improved PFS and OS with the quad therapy Isa-Vrd vs Vrd alone in transplant ineligible NDMM patients was well received by HCPs.

Topics of discussions (type of treatment)

Volume of mentions

Most mentioned clinical trials

Most mentioned molecules

Top posts from HCPs per engagement

Focus on molecular testing

KIM-1 has been highlighted as a novel potential prognostic and predictive biomarker for adjuvant RCC patients. IMmotion-010 is the associated trial. This development generated considerable interest from online HCPs.

CLEAR was the most mentioned trial. It showed that genomic signatures did not help select therapy for RCC patients according to online HCPs.

Topics of discussions (most mentioned biomarkers)

Volume of mentions

Most mentioned cancers

Most mentioned clinical trials

Reactions from HCPs on KIM-1/CLEAR

Comparison year to year

• The total number of mentions related to ASCO 2024 was significantly up at 31% when compared to 2023 going from 8k mentions to 107K mentions in 2024.
  
  
• The volume of mentions from HCPs slightly went up 2% year to year going from 30,240 in 2023 to  30,915 in 2024.
  
  
• The volume of mentions from pharma companies went up when compared to last year, going from 835 in 2023 to 899 in 224, an increase of 8%.
  
  
• The volume of mentions from organizations was down going from 10136 in 2023 to 8328 in 2024, a decrease of 18%.
  

mRCC synditrack : a bi-monthly study focused on the patient and your market needs

 

mRCC syndicated tracker: eu5 + new in 2023: china

Metastatic Urothelial Carcinoma (mUC): Real World Evidence

Find out more about Social Media Intelligence just here!